George Freeman

Pharma reaction to the Government’s AAR review

October 27, 2015
Manufacturing and Production, Research and Development Accelerated Access Review

The long-awaited interim report on the Government’s Accelerated Access Review has been published.The Government department overseeing the report, the Office …

Shire image

New Phase III data puts Shire’s lifitegrast back on track for 2016 launch

October 27, 2015
Research and Development Shire, dry eye disease, lifitegrast

Shire shares rose 6% today as the company reported new positive Phase III trial data for lifitegrast in the treatment …

Europe flag

EMA launches scheme to prioritise medicines access for patients

October 27, 2015
Manufacturing and Production EMA, European Medicines Agency, medicines access

The EMA has launched a public consultation on a scheme which aims to enable access to more medicines.The PRIME scheme …

nhsa

North of England secures new ‘centres of excellence’ in ‘precision medicine’

October 27, 2015
Manufacturing and Production, Research and Development NHS, Northern Health Science Alliance, UK

The umbrella group formed by the leading northern universities, teaching hospitals and Academic Health Science Networks – the Northern Health …

Kadcyla

Roche under pressure to drop price of Kadcyla

October 27, 2015
Manufacturing and Production Cancer Drugs Fund, Kadcyla, Roche, breast cancer

The UK’s largest breast cancer charity has called for drug manufacturer Roche to drop the price of Kadcyla before it …

Revealed: recommendations from the Accelerated Access Review

October 27, 2015
Manufacturing and Production, Research and Development Accelarated Access Review, NHS

Ministers have been urged to introduce conditional approvals for innovative new drugs, and ‘radically new’ central agreements on drug pricing, …

novartissunlight_copy

Novartis misses Q3 forecast with $390m settlement payment, strong dollar

October 27, 2015
Manufacturing and Production, Sales and Marketing Alcon, Novartis, Sandoz

Novartis reported lower-than anticipated third quarter earnings on Tuesday, hit by the $390 million settlement it has agreed to pay …

j

Valeant CEO rejects fraud accusations in conference call

October 27, 2015
Manufacturing and Production, Medical Communications, Sales and Marketing

Valeant says it will establish a committee to review allegations about the company’s relationship with specialist pharmacy Philidor, following what …

gsk_hq

GSK’s Volibris gets pulmonary arterial hypertension approval in Europe

October 26, 2015
Research and Development, Sales and Marketing EMA, GSK

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion …

imprimis_logo

Imprimis launches low-cost Daraprim alternative

October 26, 2015
Sales and Marketing Daraprim, Imprimis, Martin Skhreli, turing

Imprimis Pharmaceuticals has announced that it has made available a customisable compounded formulation of pyrimethamine and leucovorin accessible for physicians …

valeant_logo_on_board

CEO prepares for day of reckoning over Valeant fraud allegations

October 26, 2015
Sales and Marketing J. Michael Pearson, Valeant

Troubled Valeant Pharmaceuticals last week announced strong third quarter revenues, reporting a 36% increase in revenues to $172 million, but …

robert_langer

Puretech Health co-founder and board member Dr Robert Langer wins global engineering prize

October 26, 2015
Manufacturing and Production, Research and Development, Sales and Marketing Dr Robert Langer, Engineering, PureTech Health, Queen Elizabeth engineering prize

Dr Robert Langer, the co-founder of PureTech Health, has won the Queen Elizabeth prize for engineering.The award is in recognition …

AZ sign

FDA backs AZ gout drug despite safety concerns

October 26, 2015
Sales and Marketing AstraZeneca, Zurampic, gout, lesinurad

FDA reviewers have recommended approving AstraZeneca’s new gout therapy Zurampic, which the company purchased in a $1.3 billion buyout, despite …

shire_image_4

Shire reports 7% product sales growth, continues Baxalta pursuit

October 23, 2015
Sales and Marketing Baxalta, Shire

Shire has exceeded market expectations as it reported an 11% rise in Q3 earnings on Friday, driven by product sales, …

cosentyx_logo

Novartis’ Cosentyx gets European approval for two conditions

October 23, 2015
Medical Communications, Sales and Marketing Cosentyx, European Medicines Agency, Novartis, psoriatic arthritis

The scientific committee of the European Medicines Agency (EMA) has recommended the approval of Novartis’ Cosentyx (secukinumab) for treatment of ankylosing …

amgen_hq

Amgen skin cancer drug gets European approval

October 23, 2015
Research and Development Amgen, Imlygic, melanoma, skin cancer

Amgen’s Imlygic (talimogene laherparepvec) has been approved by the scientific committee of the European Medicines Agency (EMA) for the treatment of adults …

richard_erwin

New general manager for Roche UK

October 23, 2015
Medical Communications

Richard Erwin has joined Roche as the new UK General Manager.Richard’s passion for driving sustainable change and championing patient needs …

Viekira Pak logo

FDA warns AbbVie hep C drugs linked to serious liver damage

October 23, 2015
Medical Communications AbbVie

AbbVie stocks tumbled 14% yesterday after the FDA warned that two of the company’s hepatitis C drugs could cause serious …

OLS backs UK to become global digital health leader

October 23, 2015
Medical Communications Big Data, Office for Life Sciences, digital health, health analytics, mhealth, patient records, telehealth, telehealthcare

The UK market has the potential to lead the world in digital health – if certain barriers are overcome – …

The Gateway to Local Adoption Series

Latest content